Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
Register now for FREE unlimited access to Reuters.com
Aug 17 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved bluebird bio’s (BLUE.O) gene therapy for patients with a rare disorder requiring regular blood transfusions, and the drugmaker priced it at a record $2.8 million.
The approval sent the company’s shares 8% higher and is for the treatment of beta-thalassemia, which causes an oxygen shortage in the body and often leads to liver and heart issues.
The sickest patients, estimated to be up to 1,500 in the United States, need blood transfusions every two to five weeks.
Register now for FREE unlimited access to Reuters.com
The therapy, to be branded as Zynteglo, is expected to face some resistance from insurers due to its steep price, analysts say.
Gene therapies usually come with a high price tag as they are often curative and have faced hurdles in securing insurance coverage.
For instance, Novartis (NOVN.S) was in 2019 forced to offer discounts and work out “outcome-based” installments payments for its $2.1 million therapy Zolgensma after insurers balked at the drug’s price.
Bluebird has pitched Zynteglo as a potential one-time treatment that could do away with the need for transfusions, resulting in savings for patients over the long term.
The average cost of transfusions over the lifetime can be $6.4 million, Chief Operating Officer Tom Klima told Reuters before the approval. “We feel the prices we are considering still bring a significant value to patients.”
Bluebird has been in talks with insurers about a one-time payment option.
“Potentially, up to 80% of that payment will be reimbursed if a patient does not achieve transfusion independence, they (insurers) are very excited about that,” Klima said.
The FDA warned of a potential risk of blood cancer with the treatment but noted studies had no such cases.
Bluebird expects to start the treatment process for patients in the fourth quarter. No revenue is, however, expected from the therapy in 2022 as the treatment cycle would take an average of 70 to 90 days from initial cell collection to final transfusion.
Register now for FREE unlimited access to Reuters.com
Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya Soni
Our Standards: The Thomson Reuters Trust Principles.
Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval & Latest News Update
Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval & More Live News
All this news that I have made and shared for you people, you will like it very much and in it we keep bringing topics for you people like every time so that you keep getting news information like trending topics and you It is our goal to be able to get
all kinds of news without going through us so that we can reach you the latest and best news for free so that you can move ahead further by getting the information of that news together with you. Later on, we will continue
to give information about more today world news update types of latest news through posts on our website so that you always keep moving forward in that news and whatever kind of information will be there, it will definitely be conveyed to you people.
Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval & More News Today
All this news that I have brought up to you or will be the most different and best news that you people are not going to get anywhere, along with the information Trending News, Breaking News, Health News, Science News, Sports News, Entertainment News, Technology News, Business News, World News of this made available to all of you so that you are always connected with the news, stay ahead in the matter and keep getting today news all types of news for free till today so that you can get the news by getting it. Always take two steps forward
Credit Goes To News Website – This Original Content Owner News Website . This Is Not My Content So If You Want To Read Original Content You Can Follow Below Links